NFKB1 and lung carcinoma: In lung cancer cells, NF-κB activated by mutant p53 or KRAS protected cells from cisplatin- or paclitaxel-induced apoptosis, while the NF-κB inhibitor PS1145 suppressed the growth of resistant cells [107].